Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases.
It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilsonâs disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimerâs disease and Progeria.
The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022.
Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.
